Nikol Agadzhanian

Nikol graduated from St. Petersburg State Institute of Technology (Technical University), Russia, with a B.Sc. in Biotechnology, followed by an M.Sc. in Molecular Biology and Biotechnology from ITMO University, SCAMT Institute, also in St. Petersburg, Russia. Her bachelor’s thesis focused on the synthesis of iron oxide nanoparticles and their internalization into FetMSC stem cells in vitro, followed by a master’s thesis investigating the reduction of copper (II) as a strategy for overcoming drug resistance in tumor cells. She then completed an internship at the University of Bordeaux, where she studied the influence of microenvironment on the physiology of adult stem cells derived from wisdom teeth. She later joined the Müschen Lab at Yale University as a Postgraduate Associate, where she contributed to research on targeting β-catenin degradation via GSK3β inhibition as a mechanism to induce cell death in acute lymphoblastic leukemia.

She is currently working with Dr. Aline Herlopian, contributing to multiple clinical trials in epilepsy care and conducting independent research on the effects of long-term cannabidiol use on lipid panels in patients with epilepsy.